Sign in
WithdrawnNo phase

A Clinical Evaluation of Semen Quality Using the MiOXSYS™ System 2.0

Key facts

Who runs it
Aytu BioPharma, Inc.
Where
Cleveland, Houston, Miami, New Orleans, Odessa, and Rochester, United StatesSee the 6 sites
Trial code
Status
Withdrawn
Started
Sept 2025
Ended
Apr 2026
Type of study
Observational, 2 groups
Treatments tested
  • Diagnostic
Record updated
8 March 2024
Why it stopped
Study halted prematurely, prior to enrollment of first participant

Who can take part

Age
21 years to 45 years
Sex
Men only
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Between 21 and 45 years of age, inclusive
  • Male at birth
  • Sexually abstinent for a minimum of 48 hours
  • Sexually abstinent for no more than 7 days
  • Provides written informed consent
  • Agrees to complete all aspects of the study

Who cannot take part

  • Study participant on a previous date
  • Surgery in the previous 90 days
  • Trauma in the previous 90 days
  • Diagnosed and/or is taking chronic medication for a chronic gastrointestinal condition including irritable bowel syndrome, colitis, or similar metabolic dietary conditions
  • History of prostate cancer or any cancer that has been active over the last 5 years
  • White blood cells and/or round cells are greater than or equal to 1 million sperm/mL
  • Diagnosis of azoospermia
  • Unable to complete all aspects of the study
  • Enrolled in another clinical study at the time of screening
  • Vasectomy
  • Takes additional daily antioxidant supplements including Vitamin C, Beta-Carotene, Vitamin E, Zinc, N-acetylcysteine, or Selenium. Multivitamin is acceptable for inclusion into the study
  • Semen sample does not liquefy in 60 minutes
  • Sperm concentration in semen sample is less than 1 million sperm/mL

Where in United States

  • Cleveland ClinicCleveland, United States
  • Baylor College of MedicineHouston, United States
  • University of MiamiMiami, United States
  • Tulane UniversityNew Orleans, United States
  • Odessa Regional Medical CenterOdessa, United States
  • Mayo ClinicRochester, United States

About the trial

What the trial wants to find out

The purpose of this study is to determine if elevations in oxidative stress, as measured by oxidation-reduction potential (ORP), can distinguish between semen samples from men with abnormal semen parameters from those with normal semen parameters. Static ORP (sORP) results, measured by the MiOXSYS System- a novel technology, will be compared to the current World Health Organization (WHO) semen analysis parameters (5th Edition WHO Laboratory Manual for the Examination and Processing of Human Semen [2010]).

The 2 groups in the trial

  • Normal Semen

    Semen that meet the criteria for "normal" on sperm number, motility, and morphology as described by the current WHO manual.

    Treatment: Diagnostic

  • Abnormal Semen

    Semen that fail to achieve one or more of the criteria for "normal" on sperm number, motility, and morphology as described by the current WHO manual.

    Treatment: Diagnostic

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
8 March 2024